Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?

被引：21

作者：

Lisco, Giuseppe ^{[1
]}

De Tullio, Anna ^{[1
]}

Disoteo, Olga ^{[2
]}

Piazzolla, Giuseppina ^{[1
]}

Guastamacchia, Edoardo ^{[1
]}

Sabba, Carlo ^{[1
]}

De Geronimo, Vincenzo ^{[3
]}

Papini, Enrico ^{[4
]}

Triggiani, Vincenzo ^{[1
]}

机构：

[1] Univ Bari Aldo Moro, Sch Med, Interdisciplinary Dept Med, Sect Internal Med Geriatr Endocrinol & Rare Dis, Piazza Giulio Cesare, Bari, Italy

[2] ASST Grande Osped Metropolitano Niguarda, Diabetol Unit, Milan, Italy

[3] Policlin Morgagni CCD, Unit Endocrinol, Catania, Italy

[4] Regina Apostolorum Hosp, Dept Endocrinol & Metab, Rome, Italy

来源：

ENDOCRINE CONNECTIONS | 2023年 / 12卷 / 11期

基金：

英国科研创新办公室;

关键词：

dipeptidyl peptidase IV; glucagon-like peptide 1 receptor agonist; incretin system; medullary thyroid cancer; papillary thyroid cancer; GLP-1; RECEPTOR; CALCITONIN CONCENTRATIONS; LIRAGLUTIDE; RISK; IV; METASTASIS; EXPRESSION; BENEFITS; INCREASE; OBESITY;

D O I：

10.1530/EC-23-0257

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer. In this perspective, the role of the incretin system in thyroid carcinogenesis has been reviewed and critically commented on, aiming to understand if the time has arrived to be concerned about the risk. Although evidence suggested, speculative hypotheses should be verified, and further studies are urgently needed to clarify the issue.

引用

页数：7

共 61 条

[1] Thyroid Cancer Screening in South Korea Increases Detection of Papillary Cancers with No Impact on Other Subtypes or Thyroid Cancer Mortality [J].